Alterations of Nutritional Status in Childhood Acute Leukemia by Maldonado-Alcázar, Alejandra et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 12
Alterations of Nutritional Status in
Childhood Acute Leukemia
Alejandra Maldonado-Alcázar,
Juan Carlos Núñez-Enríquez,
Carlos Alberto García-Ruiz,
Arturo Fajardo-Gutierrez and
Juan Manuel Mejía-Aranguré
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52715
1. Introduction
Nutritional  status  is  the  result  of  the  interaction  between  environmental  and  genetic
conditions  in  which  a  child  lives,  when  these  environmental  conditions  are  favorable
for  life  (physical,  biological,  nutritional  and  psychosocial),  the  genetic  potential  is  ex‐
pressed as an ideal state of nutrition, but when conditions are unfavorable such expres‐
sion  will  be  diminished,  resulting  in  altered  nutritional  status,  such  as  malnutrition,
overweight  and  obesity,  which  among  other  things  would  cause  the  child  did  not  re‐
spond to a disease or its treatment suitably at a given time. [1]
In  different  studies  conducted  in  children  with  cancer,  the  authors  have  evaluated  the
impact  of  nutritional  status,  assuming  that  if  a  cancer  patient  is  well  nourished,  have
less  toxicity  caused  by  antineoplastic  drugs,  will  have  a  greater  immune  resistance  to
processes serious infectious, and therefore have a better survival and quality of life than
the patient who is  not well  nourished, so in this chapter we will  mention the most im‐
portant conclusions that have been made with respect to this issue. [2]
Malnutrition is the main nutritional disorder that occurs in children with cancer, and has
been  defined  as  a  state  in  which  a  deficiency  of  energy,  protein,  and  other  nutrients,
causes measurable  adverse effects  on the structure and functioning of  organs and body
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tissues as well as the clinical course of a disease. In order to explain the mechanisms by
which it  causes  malnutrition in children with cancer,  three factors  have been proposed:
a)  factors  specific  to  the  tumor  (tumor  growth  factors  released  by  the  tumor  cells  as
bombesin  and  adrenocorticotropic  hormone)  b)  factors  related  to  the  patient  (pediatric
age,  low socioeconomic  status,  poor  nutrient  intake,  increased  secretion  of  growth  hor‐
mone and cytokines that are released by the body in response to tumor growth, among
the most important are the tumor necrosis factor, interleukins 1 and 6), and last but not
least, c) factors related to the treatment (type / dose of chemotherapy, site / dose of radi‐
otherapy and surgery).  It  is  also suggested that  all  these factors  would cause an altera‐
tion  in  intermediary  metabolism,  with  resultant  decrease  in  appetite,  which  eventually
lead to the patient to lose weight, creating a vicious cycle. [2-6]
1.1. Prevalence of malnutrition in children with cancer
It has been reported that children with cancer will develop signs and symptoms of malnutri‐
tion at some point in the disease by up to 50-60% of cases, however, this frequency may vary
according to the type of neoplasm, and according to if the study was conducted in devel‐
oped countries or in developing countries, where there has been an increased frequency of
nutritional alterations. It should be mentioned, that the study of the prevalence of malnutri‐
tion in children with cancer is mainly determined by whether it is present at diagnosis, this
is important because it also could establish their potential impact on the evolution of these
patients before treatment started. [7,8]
In this regard, Brinksma A, et al., (2012) reported the prevalence of malnutrition at diag‐
nosis for developed countries, through a systematic review which included patients with
different types of childhood cancer, aged from 0-18 years of age for acute leukemias, the
prevalence was 10%, 20-50% for neuroblastoma, and those classified as "other malignan‐
cies" was 0-30%, these prevalences are low when compared with those that have been es‐
timated  for  developing  countries  where  they  are  as  high  as  50%  for  all  types  of
childhood cancers. [2,8,9]
2. Nutritional status assessment in children with acute leukemia
There are several clinical, biochemical and physiological indicators to diagnose malnutri‐
tion  in  children  with  cancer;  such  as  the  patient’s  age,  the  deficit  of  specific  micronu‐
trients  and  the  presence  or  absence  of  infection.  The  severity  of  their  malnutrition  is
determined  mainly  by  anthropometric  indicators,  that  are  the  indexes  of  weight-for-
height  (w/h)  and  weight-for-age  (w/a),  which  indicates  acute  malnutrition  (table  1),
height-for-age  (h/a)  which  indicate  a  delay  in  growth  or  chronic  malnutrition;  and  the
Body Mass Index (BMI),  which is  a  figure that  can diagnose a patient  for  being under‐
weight, overweight or obesity. [10,11] (table 4)
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Percentile Diagnosis
<5 Malnourished
5-85 Normal
> 85 a < 95 Overweight
≥ 95 Obesity
Table 1. Diagnosis by percentile for the indexes weight-for-height, weight-for-age based on the World Health
Organization (WHO) tables.
Waterlow´s Classification:
Denomination Index Classification
Wasting Weight-for-height <5 Acute Malnutrition
Stunting Height-for-age <5 delay in growth or chronic malnutrition
Table 2. Denomination of wasting and stunting with Waterlow´s classification. [12, 13]
Waterlow´s classifications:
Denomination Index Classification
Wasting, no stunting Weight-for-height <5 ,height-for-age Normal Acute malnutrition
Wasting and stunting Weight-for-height <5 ,height-for-age <5 Exacerbated-chronic malnutrition
Stunting, no wasting Weight-for-height Normal,height-for-age <5 Chronic malnutrition
Table 3. Combinations of nutritional diagnosis with Waterlow’s classification. [12,13]
Percentil Diagnosis
<5 Underweight - Malnourished
≥5 y <85 Normal
≥85- <94 Overweight
≥95 Obesity
Table 4. Diagnosis by percentile for the Body Mass Index (BMI) based on the World Health Organization (WHO) tables [10]
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It’s important to consider the body composition in children with cancer, with which we are
able to determine the quantity of lean mass and body fat in their bodies, in order to see if
there is muscular depletion. The anthropometric measures used to get body composition
can be the Mid Upper Arm Circumference (MUAC), triceps (TSF), biceps, subscapularis and
suprailiac skinfolds; [14] and in case of having the necessary equipment, the use of electric
bioimpedance or D-XA (Dual X-Ray Absorptiometry) is recommendable.
With the mid upper arm circumference and the triceps skinfold, you can calculate the mus‐
cle and fat area by using the following formula:
Then comparing the score with the Frisancho tables where:
Percentile Diagnosis
0 – 5 Wasted
5.1 – 15 Below average
15.1 – 85 Average
85.1 - 95 Above Average
>95 High muscle
Table 5. Diagnosis by percentile for upper arm muscle area based on Frisancho tables. [14]
Aside from those anthropometric indicators, there are biochemical indicators that are used
to diagnose protein malnutrition, like albumin and pre-albumin which are the most impor‐
tant due to their hepatic synthesis, and total protein. [15,16]
The half- life of albumin is 20 days, therefore it can assess acute malnutrition and can be
used as a morbidity and mortality prognosis factor.
Reference value Diagnosis
3.5 - 5.5 g/dl Well-nourished
2.8 - 3.5 g/dl Malnourished Grade 1
2.1 - 2.7 g/dl Malnourished Grade2
< 2.1 g/dl Malnourished Grade 3
Table 6. Albumin reference values and diagnosis [15]
Prealbumin has a 2 days half life wich means it is a very sensible marker for acute malnutrition,
but the result may be affected by inflammatory reaction, therefore is not useful to track changes
on the nutritional status unlike albumin that can be a better marker for protein malnutrition. [16]
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Reference value Diagnosis
17 - 42 g/dl Well-nourished
<17 g/dl Malnourished
Table 7. Prealbumin reference values and diagnosis [17]
It is important to make a full assessment of nutritional status in these children as this can
influence the patient's response to the treatment.
3. Impact of malnutrition in Acute Lymphoblastic Leukemia (ALL)
The study of the impact of malnutrition in children with cancer has been conducted pri‐
marily  in  patients  with  acute  leukemia,  specifically  in  (ALL)  perhaps  because  it  is  the
most common type of cancer in children worldwide. [18-21] In two papers published one
by Underzo et al., and in another by Reilly J, et al., reported that the prevalence of mal‐
nutrition at diagnosis in patients with ALL was 7% for developed countries, and on the
contrary,  in  different  studies  conducted  in  developing  countries  have  reported  higher
prevalence of up to 21-23%, which confirms the statement that in countries with low eco‐
nomic development, malnutrition occurs more frequently, This could be a result of pov‐
erty.  It  is  for  this  reason  that  for  several  years,  these  countries  have  made  efforts  to
determine  the  true  impact  of  malnutrition  as  a  prognostic  factor  in  patients  with  acute
leukemia in children at different stages of treatment. [22-25]
3.1. Prognosis
As is known chemotherapy used in the treatment of patients with ALL has some serious ef‐
fects that may endanger the life of patients at a given time. Among the most common side
effects of QT are toxicity to various organs, infection, hemorrhage, tumor lysis syndrome
(TLS), among others., which would be the cause of high morbidity and mortality. It is for
this reason that the current chemotherapy protocols in children with ALL are based on a
risk classification to reduce toxicity in low-risk patients as well as ensure that therapy is ade‐
quate and aggressive to those classified as high risk. [26,27]
In the group of patients with ALL who are malnourished at diagnosis, it was found that che‐
motherapy is more toxic and less effective compared to those found with adequate nutri‐
tional status, specifically haematological toxicity is the cause of most complications, such as
an increased risk to present infections, bleeding and an increased risk of relapse, the above
due to neutropenia, thrombocytopenia, and discontinuation of treatment, respectively.
The main effect of malnutrition on treatment, is due to an alteration of the biodisponibility
of antineoplastic drugs, which is achieved through the following mechanisms: a) changes in
absorption, eg for drugs like methotrexate and 6 mercaptopurine, b) the decreased drug
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transport by the reduction or lack of plasmatic proteins, and c) by decrease in hepatic metab‐
olism of the antineoplastic mainly caused by a lack of enzymatic activity by cytochrome
P450. [28-37]
Furthermore. highlight the importance of studying on the subject of how malnutrition af‐
fects the prognosis of patients with ALL, because in some of the studies did not allow con‐
clusions to determine whether the association exists in some of these studies were given the
limitations by factors such as inadequate sample size, the inconsistency in how to assess the
nutritional status between studies, and also have not been studied other possible complica‐
tions in the evolution of these patients, such as relapse, abandonment in the treatment,
among others. [28,38-40]
3.2. Survival
Moreover, since 1980 the rates of event-free survival has improved in patients with ALL,
currently  reported survival  at  5  years  is  80% and 10-year  survival  is  60% in developed
countries,  however,  in  developing countries  cure rates  are  less  than 35%, so on a quest
to determine the factors related to mortality in developed countries, but mainly in devel‐
oping countries, has been studied by different authors on the role of malnutrition on sur‐
vival  of  patients  with  ALL;  remain  controversial  until  now  because  while  on  the  one
hand, some authors have reported that survival rates are lower in malnourished patients
compared with patients who are well nourished and of the same risk, in other studies, it
has  not  been possible  to  confirm this  association.  [8,29,41]  According to  Reilly  J,  et  al.,
There are three mechanisms that explain the direct influence of malnutrition on survival
of patients with ALL: The first,  means that if  there is a greater severity of malnutrition,
there  will  be a  greater  severity of  leukemia this  because as  we know, malnutrition is  a
surrogate  marker  of  the  disease  state,  the  second mechanism is  related to  immune sys‐
tem dysfunction that occurs in malnourished patients, which would cause increased sus‐
ceptibility  to  potentially  serious  infections  could  lead  to  the  death  of  the  patient,  and
finally, a mechanism related to adipose tissue, which has as one of its main functions be‐
ing a facilitator to take place the pharmacokinetics of many anticancer drugs, this tissue
is functionally and structurally altered in malnutrition, resulting in a lower effective anti‐
neoplastic drugs and greater toxicity and that both could be potential factors sufficient to
endanger  the  patient's  life,  however  this  mechanism has  been studied by other  authors
who found no such effect. [23-39]
Therefore, it is believed that malnutrition alone is a major factor in poor prognosis and sur‐
vival of patients with ALL, however, it is noteworthy that most of the studies performed,
are from developed countries and / or where it is mainly evaluated the impact of malnutri‐
tion on long-term survival, so it is necessary to know whether the association also exists in
developing countries, because these populations have certain characteristics, such as fre‐
quencies malnutrition and deaths occur primarily during the first year of treatment much
higher, and it also has been reported as one of the main obstacles to improved survival rates
in patients with ALL. [39,42-45]
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3.3. Malnutrition and early mortality
Early mortality can be defined as death during the first year of treatment, and it includes treat‐
ments as chemotherapy of induction to remission, central nervous system prophylaxis and con‐
solidation. In several cases around the globe, the early mortality rate for developed countries is
significantly lower than the one presented in developing countries. Main causes for early mor‐
tality include complications during chemotherapy treatment, such as infections, hemorrhages
and toxicity, since their presence often represent an interruption in the treatment.
A 1999 study conducted by Silverman and collaborators in the Dana-Farber Cancer Institute,
United States; a mortality rate of 2% in the first stage of treatment was reported, mainly
caused by infections. [46] Another study conducted in the UK in 1997 also measured the rate
of early mortality in these patients, reporting a mortality rate of barely 1.2%, with infections
still being the main cause of death; however, cases of brain hemorrhage and tumor lysis syn‐
drome (TSL) were also detected. [47]
The country that reports the lowest percentage of mortality in early stages of treatment is
Germany, which reported only a 1% death rate in their patients between 1984 and 1996; with
most of the deceases caused by hemorrhages and tumor lysis. [41]
While that’s the case in developed countries, where very low mortality rates are reported; a
study conducted by Rivera Luna and collaborators in Mexico’s Instituto Nacional de Pedia‐
tría (INP) threw results of a 15% mortality rate during the phases of induction to remission.
[37] In other developing countries like Honduras, El Salvador, Brazil, and India mortality al‐
so shows a spike in rates compared to developed countries, with an early mortality rate of
20.8%, 12.5%, 14.9% and 17% respectively, as you can see in Graph 1. [48-51]
 
 
 
Germany U.K. U.S.A El Salvador Brazil Mexico  India Honduras 
1% 1.20% 2% 12.50% 15% 15% 17% 21% 
 
Graphic 1. Incidence of early mortality in patients with ALL around the world.
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A  possible  explanation  for  this  marked  difference  might  be  that  malnutrition,  poverty
and lack  of  access  to  public  health  services  are  frequent  problems in  developing  coun‐
tries,  unlike  developed  countries  where  children  with  leukemia  have  lower  early  mor‐
tality  rates.
There have been several studies that try to correlate malnutrition with the evolution of pa‐
tients with ALL. The first one was conducted in Mexico in 1989 by Lobato Mendiazabal et
al., where there’s a categorization of children with or without malnutrition based on weight-
for-height indicators. It was found that, when measuring 5 year survival rate, 80% of chil‐
dren without malnutrition survived, while patients with malnutrition had a survival rate of
barely 26% in the same period. [44]
As  far  as  early  mortality  and  relapses  during  the  first  year  of  treatment  go,  only  4%
of  children  diagnosed  with  good  nutrition  suffered  any  of  those  events,  while  63%  of
ill  nurtured children experienced a  relapse or  death.  This  study was conducted in Pue‐
bla,  with a sample size of  42 children of  a  single hospital  facility (Hospital  Universitar‐
io  de Puebla).  [44]
In a case and control study conducted by Mejia Aranguré and collaborators the state of nu‐
trition of several patients with the weight-for-height indicator was tested and compared for
diagnosis with the boards of Federico Gómez. For this study 93 cases of 2 hospital sources
were taken; Hospital Infantil Federico Gómez and Hospital de Pediatría de Centro Médico
Nacional S XXI. [35]
It  was  found  that  children  with  malnutrition  at  the  moment  of  diagnosis  were  almost
2.6  times  more  likely  to  die  in  comparison to  children without  malnutrition.  Therefore,
it  was  concluded  that  malnutrition  is  a  factor  that  increases  the  mortality  rate  of  chil‐
dren  with  ALL,  and  an  association  directly  proportional  to  the  severity  of  the  nutri‐
tion was established.  [24]
In a prospective cohort conducted in 63 patients by Khan and collaborators, malnutrition
was classified with the index of weight-for-height, and the result was that 46% of children
with malnutrition at the moment of ALL diagnose completed their treatment; only 9.8% suf‐
fered a relapse and 45% died; meanwhile children without malnutrition experienced a 59%
survival to their treatment, a 21% relapse rate and 19% died. Thus, malnutrition was consid‐
ered as a bad prognosis factor for children with ALL. [36]
One of the most recent studies was conducted in Bangladesh by Hafiz MG and collaborators
in 2008. This study only takes a sample of 66 patients from the Indian Pediatric Hospital, the
index they used was the weight-for-height measurement, although they don’t specify the ta‐
bles that results were compared to in order to classify the state of nutrition.
They concluded that children that present malnutrition have 2 to 3 times the risk of infection
in comparison to children without malnutrition. It was also observed that children with mal‐
nutrition needed more time for induction therapy since their dosage has to be lowered, or
their treatment was interrupted for toxicity. [28]
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Another study realized by Pedrosa F. and collaborators in 2000, took in account indicators as
weight-for-height, height-for-age and weight-for-age; comparing them to WHO data. For
this study they took in account patients with any type of leukemia and patients with solid
tumors. This study was collaboration between two hospitals in El Salvador and Brazil,
where they were able to include 443 patients. Of that number, 151 had an ALL diagnosis. At
the beginning of the study children were classified as children with malnutrition and chil‐
dren without malnutrition, and children with malnutrition were provided with a dosage of
albumin 2 weeks before starting chemotherapy. The study concluded that “malnourishment
doesn’t have a relevant association with these patients’ survival”. [38]
The most recent study published on this subject was conducted with patients of Mexico’s
Instituto Nacional de Pediatría, with 100 patients diagnosed with ALL. Their state of nutri‐
tion was determined with indicators of weight-for-height and height-for-age and compared
to the NHANES tables of the CDC in the United States. This was a retrospective study
where the follow up was done during the phases of induction to remission, and the results
were as follow: 14.9% of children without malnourishment died during treatment phase,
while 5.1% of patients without malnourishment perished in this stage of treatment There‐
fore, it was concluded that malnutrition didn’t play an important role in early mortality in
children with ALL. [37]
In a retrospective cohort done in El Salvador with 469 patients, besides BMI index, triceps
skinfolds and Mid Upper Arm Circumference were taken into consideration. This study
concluded that malnourishment had no association with mortality during treatment. [49]
A study conducted by Hijiya and collaborators demonstrated with a retrospective cohort of
621 patients of St. Jude’s Hospital in United States concluded that BMI didn’t affect the evo‐
lution of patients with ALL. This study took BMI as the main nutritional indicator and div‐
ided children in 3 groups: malnourished, normal and obese. The survival rates in these
categories were similar, children with malnutrition presented a survivability rate of 86.1%,
children with a normal nutrition state had an 86% survivability rate and in obese children
the figure was of 85.9%. [39]
There’s controversial information about the relationship between the effects of malnutrition
in the evolution of patients with ALL, mostly because even with a wide range of studies,
some conclude there’s a significant relation between these factors [24,28,44] while others
conclude that there’s no relation. [37-39, 49]
One of the reasons is the bias in the classification of malnutrition, since in some studies like
Pedroza and collaborators [38] the World Health Organization (WHO) charts are used, and
in Rivera Luna and collaborators [37] they used the charts of the National Health and Nutri‐
tion Examination Survey (NHANES), while in the study conducted by Lobato Mendizabal
and collaborators the charts of Ramos Galván were taken into account [44] and at last the
study of Mejía Aranguré and collaborators used Federico Gómez’ charts. [24]
In the studies mentioned, the sample was taken only from one or two hospital sources, so
it’s important to conduct a multicentre study that can show a wider panorama of the effects
of malnourishment in the evolution of children with ALL.
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Autor
(Year)
Lobato
Mendiazabal
et al.
(1989)
Mejía Aranguré et
al.
(1999)
Pedrosa F.
et al.
(2000)
Rivera Luna
et al.
(2005)
Country Mexico Mexico El Salvador and Brazil Mexico
Hospitals Centro de
Hematología
Medicina Interna and
Hospital Universitario
de Puebla
Hospital de Pediatría
S. XXI and Hospital
Infantil de México
Federico Gómez
Hospital de niños
Benjamín Bloom and
Instituto Materno-
Infantil de
Pernambuco
Instituto Nacional de
Pediatría
Type of study Prospective cohort Case- control Retrospective Cohort Retrospective Cohort
Sample size 43 patients 93 patients,
17 cases and
76 controls
443 patients
151 with ALL
100 patients
Age 1-15 years <16 years 0-17.8 years 0-15 years
Parameters used Weight-for-age Weight-for-height Weight-for-age,
Height-for-age
Weight-for-height
Height-for-age,
Weight-for-height
Classification Ramos- Galvan’s
Tables
Federico Gómez
Tables
WHO`s Tables National Health and
Nutrition
examination survey
NHANES
Results 5-year survival in well
nourished versus
malnourished
patients:
83% in well
nourished Vs 26% in
malnourished. Death
and relapses: 4% in
well nourished vs.
63% malnourished.
Reduction of
chemotherapy
treatment: 75% in
well nourished Vs.
56% malnourished.
Children who had
malnutrition at the
time of diagnosis
were 2.6 more likely
to die than children
without malnutrition;
therefore
malnutrition
increases mortality in
children with LLA.
Malnutrition has no
association with
survival of patients
Note: A dose of
Albumin was applied
to malnourished
children 2 weeks
before they started
treatment.
14.9% of well
nourished children
died during the
induction to
remission therapy;
15.1% of
malnourished
children died during
the same stage of
treatment,
“Malnutrition does
not play a role in
early mortality in
children with ALL”.
Country USA Pakistan Bangladesh El Salvador
Hospitals St. Jude´s
Children Research
Hospital
Shaukat Khanum
memorial Hospital
Pediatric Hematology
and Oncology
Hospital de niños
Benjamín Bloom
Type of study Retrospective cohort Prospective cohort Prospective cohort Prospective Cohort
Sample size 621 patients 163 patients 66 patients 469 patients
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Autor
(Year)
Lobato
Mendiazabal
et al.
(1989)
Mejía Aranguré et
al.
(1999)
Pedrosa F.
et al.
(2000)
Rivera Luna
et al.
(2005)
Age 1-16 years <14 years 1-15 years 0-16 years
Parameters used BMI Weight-for-height Weight for age BMI, MUAC,(TSF)
Classification CDC tables Waterlow`s
Classification
Not specified CDC Tables
Results Children were
divided in 3
categories: <10°
malnourished; >ó=
85° well nourished; >
85 < 95° overweight;
>95 Obesity; Note:
Chemotherapy
dosage was not
adjusted by BMI.
Survival rate: 86.1%,
86.0%, 85.9% and
78.2% respectively
BMI has no effect on
the survival of LLA
children.
Malnourished
children: 46%
complete treatment
and were alive, 9.8%
relapse and 45%
died. Well nourished
children: 59%
complete treatment
and were alive,
21.3% relapse and
19% died.
“ Malnutrition is a
prognosis factor in
LLA children”
Malnourished
children are 3 times
more likely to present
infections tan well
nourished ones.
Malnourished
children need more
time of induction to
remission treatment
due to the dose
reduction caused by
toxicity.
Malnutrition has no
association with early
mortality in children
with LLA.
Table 8. Studies about the effect of malnutrition at time of diagnosis and early mortality in children with ALL.
4. Overweight and obesity in survivors of childhood acute lymphoblastic
leukemia
Concern about children who suffered from ALL is the long-term consequences that therapy
may bring after the leukemia has been overcome. Various studies have shown that nutri‐
tional abnormalities like obesity and overweight are commonly found in ALL survivors,
with a prevalence of 20-34% depending on the country where it has been studied. [52,53]
van Waas et al, conducted a study in 2004 in the Netherlands during the period from 2002 to
2007 in a single-center cohort of 500 survivors of childhood ALL. The ages of these patients
at the time of the study ranged from 18 to 59 years, of which 288 were females and 212 were
males, measured variables corresponded to the levels of total cholesterol, HDL cholesterol,
systolic and diastolic blood pressure, BMI, and the authors finally concluded that patients
who had been treated with cranial radiotherapy (CRT) had a higher frequency of over‐
weight (59% versus 34%, P = 0.003) than those who had not received CTR. [54]
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Obesity and overweight are defined are the result of varying degrees of abnormal or excessive
accumulation of fat. The World Health Organization defines overweight as a BMI of 25 to 29.9,
and obesity as a BMI of ≥30. The BMI modifications in survivors of childhood ALL are notewor‐
thy because they are associated with insulin resistance, diabetes mellitus, hypertension, dysli‐
pidemia and with an increased cardiovascular risk. [55]
4.1. Mechanisms involved in the development of overweight and obesity in ALL
survivors
Because of this, the processes by which these nutritional abnormalities are developed by
ALL survivors are being studied, though the exact mechanisms are still uncertain, nonethe‐
less, there are some hypotheses that would explain metabolic deregulations leading to the
development of altered BMI by the excessive accumulation of body fat. Here we will focus
on the effects due to radiotherapy and corticosteroids. However, it is important to point out
that exist other factors linked to these alterations. For example, long hospitalization periods
because of inmunosuppression or vincristine-induced peripheral neuropathy may cause re‐
stricted physical activity in these patients. In addition to this, it should not be left out the
usual risk factors for developing obesity of each population. [56]
4.1.1. Effects attributed to cranial radiation therapy
In one of the largest studies conducted so far related to the effect of radiotherapy for the devel‐
opment of overweight and obesity in ALL survivors by Oeffinger et al, (2003), reported that the
dose and radiation site were the mainly cause. This study was conducted during the period
from 1980 to 1994 the study population corresponded to 1765cases and 2588 controls aged 18-42
years old. Considering a radiation dose greater than 20Gy there was a risk factor for obesity in
men with an OR 1.86 for ills (95% CI, 1.33 to 2.57, P <.001) and in women with an OR of 2.59 (95%
CI, 1.88 to 3.55, P <0.001), without observing this nutritional disorder in patients who had re‐
ceived chemotherapy alone or had received cranial radiation doses of 10 to 19 Gy. [57]
Lackner H et al 1991and subsequently by Janiszewski et al., (2007), reported that the levels
of growth hormone (GH), insulin-like factor (IGF1) and leptin levels were significantly low‐
er in CRT than in non-CRT. [58,59]
The mechanism proposed to explain the growth hormone deficiency, holds that cranial radi‐
otherapy (CRT) given at a young age to treat children suffering from ALL, damages the hy‐
pothalamus neurons, inducing growth hormone deficiency (GHD). [60] Deficiency in the
secretion of growth hormone (GH) has been associated with the augmented percentage of
body fat. Evidence that supports these hypothesis are the decreased levels of IGF-1 (also
known as somatomedine C), which is a mediator of the GH action in target tissues.
Apart from their individual effects, there is evidence that relates leptin and GH. GH and
IGF-1 are decreased in response to fasting. Impaired GH synthesis and secretion occurs
along with a leptin deficiency or abnormality on its receptor. Leptin may also regulate GH
via somatostatin synthesis inhibition and secretion, allowing GH to yield its actions over the
targeted tissues. [61]
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Among many other physiological functions of the GH, this hormone promotes utilization of fats
as source of energy, inducing the liberation of fatty acids into the bloodstream. At the same time,
it has anabolic protein effects which are traduced in an increase of lean body mass. [62]
Moreover,  it  has  been recently  suggested that  only susceptible  individuals  will  develop
obesity when treated with CRT. This susceptibility has been tracked down to a polymor‐
phism  in  the  leptin  receptor  in  the  hypothalamus.  This  polymorphism  (Arg/Arg)  was
found by  Ross  et  al.,  to  be  associated to  females  having a  BMI ≥25,  treated with  CRT.
[63] Leptin is a hormone produced by adipocytes and it is involved in feeding behavior
regulation and energy balance. Stored energy in adipose tissue is closely watched by the
hypothalamus,  through this  hormone.  An increase in adipose tissue will  be traduced in
increased leptin  synthesis  by  adipocytes,  and by negative  feedback over  the  hypothala‐
mus food intake will be inhibited. [64,65]
4.1.2. Corticosteroid therapy
Because corticosteroids are used to treat ALL, it is important to point out that they also pro‐
mote leptin synthesis. However, conducted studies have only shown short-term effects on
increasing body weight. However, these findings strongly suggest doing more research to
determine if glucocorticoids induce long-term body weight via leptin synthesis or through
other mechanisms. [66]
After it has been released to the blood stream, leptin reaches the central nervous system
and binds to its  receptors found in the hypothalamic neurons of  the arcuate,  ventrome‐
dial, and dorsomedial nuclei. The activation of the receptors, decreases the production of
orexigenic  (or  appetite  stimulant)  substances such as  neuropeptide Y and agouti-related
peptide. It also activates the sympathetic nervous system, increasing the metabolic index
and energy consumption. As for the insulin,  leptin reduces its secretion, resulting in di‐
minished energy storage. [62]
As it has been shown leptin insensitivity, would have repercussions in the regulation of
body weight and metabolism. This leptin resistance can be attributed to abnormal receptors
as well as malfunctioning intracellular signaling. [61] Either way, disruption of the leptin
signaling, will eventually result in metabolic modifications that would lead to a raised BMI.
Furthermore, ALL survivors with CRT have higher risk of developing other components of
the metabolic syndrome. [53] Gurney at al. encountered that ALL survivors who received
CRT have increased total cholesterol levels, abnormally low HDL-C, altered triglycerides
and LDL-C, compared to those who were not given CRT. [65]
5. Conclusions
As it has been shown, treatment for ALL predisposes patients to suffer from obesity and
metabolic alterations, not only after, but also during it. Because of this, physicians should
make patients being treated for ALL and those who have overcome ALL, aware of the possi‐
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bility to develop these changes, and should strongly advise them to develop healthy life‐
styles, in order to counteract this increased risk. In addition, strict medical follow-up should
be set for the early detection of this alterations, so that adequate medical intervention and/or
habit shifts could take place before irreversible damage has occurred.
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